Early Clinical Development Built Around Biotech Innovation
Early clinical innovation advances through integrated scientific leadership, multidisciplinary collaboration and program continuity embedded from first-in-human planning through Phase II progression. Evestia Clinical provides that partnership from the earliest stages of each program.
Evestia Clinical is a Phase I CRO built around biotechnology companies. Early-phase specialists are embedded within each program, delivery adapts to program evolution and governance structures, and senior scientific leadership remains engaged throughout program delivery. Our Full-Service CRO and FSP Solutions models scale with program requirements from first dose through Phase II planning.
Senior Expert Access
Experienced early-phase specialists who remain directly engaged throughout program delivery. Faster decisions, greater scientific confidence at every milestone.
Integrated Scientific Partnership
Scientific collaboration extending well beyond operational execution, informing study design, dose escalation strategy, PK/PD interpretation and regulatory positioning.
Flexible From Day One
Delivery models that adapt to program evolution and internal team structures without imposing rigid frameworks. Full-Service CRO and FSP Solutions that scale with your program.
Built for Biotech
Operating models designed around biotechnology companies, aligned to how biotech sponsors work, fund and scale early-phase development.
Phase I Experience at a Glance
Successful Phase I programs depend on experienced clinical leadership, scientific expertise and disciplined operational delivery. These figures demonstrate Evestia Clinical's experience supporting first-in-human studies and early clinical development across complex therapeutic areas.
30+
Years Clinical Research Experience
Deep early-phase expertise
First-in-Human
Study Expertise
FIH design and delivery
PK/PD
Development Support
Integrated scientific capability
Phase I–IV
Clinical Development Continuity
Early through registration
Phase I Clinical Development Expertise for Early-Stage Programs
Entering human studies for the first time is a critical stage in clinical development. Dose selection, biomarker strategy, safety monitoring framework and proof-of-concept endpoint design all build the evidence that shapes every subsequent phase.
Evestia Clinical supports biotechnology and pharmaceutical companies across first-in-human (FIH) studies, dose-escalation programs, healthy volunteer studies, patient-based early-phase trials, drug-drug interaction (DDI) studies, thorough QT (TQT) studies, population PK (POP) studies, proof-of-concept (POC) studies and special population studies. Integrated Phase I expertise spans initial regulatory strategy and IND/CTA preparation through study design, operational delivery and the evidence generation needed for confident progression into Phase II and beyond.
Generating clean PK/PD data, maintaining participant safety and achieving program progression simultaneously benefits from scalable integrated scientific expertise. Phase I delivery at Evestia Clinical draws on Clinical Operations, Regulatory Affairs, Pharmacokinetics, Data Management and Biostatistics working as one coordinated team, with Global CRO capabilities extending early-phase reach internationally where needed.
Why Phase I Clinical Trials Matter
Phase I studies are the foundation upon which every subsequent development decision is made. The quality of evidence generated here, and the strategic decisions taken about dose escalation, biomarker strategy and safety monitoring, helps shape Phase II success rates, regulatory interaction quality and program confidence.
Sponsors who approach Phase I with the right scientific and operational foundations generate cleaner data, make faster go/no-go decisions, enter Phase II from a position of strength, and create the regulatory and development momentum that supports portfolio progression and partnership discussions.
Phase I evidence informs:
- Safety and tolerability
- Dose escalation strategies
- Maximum tolerated dose (MTD)
- Pharmacokinetic (PK) profiles
- Pharmacodynamic (PD) responses
- Early efficacy signals
- Biomarker evaluation
What Is a Phase I Clinical Trial?
Robust early evidence shapes everything from Phase II design to licensing discussions. Phase I programs achieve this through:
Safety Evaluation
Assessing the safety profile of an investigational therapy, establishing the evidence base for confident escalation and future development.
Dose Escalation
Determining safe and effective dose ranges through structured escalation designs that maximize information from every cohort.
Pharmacokinetic Assessment
Understanding how a therapy is absorbed, distributed, metabolised and eliminated, providing the exposure evidence that underpins all subsequent dosing decisions.
Pharmacodynamic Evaluation
Assessing biological responses to treatment and target engagement, generating mechanistic evidence that supports Phase II endpoint strategy.
Early Clinical Activity
Identifying initial evidence of therapeutic effect where appropriate, creating the earliest commercial signal for investors and potential partners.
These studies establish the foundation for Phase II and Phase III development success.
First-in-Human (FIH) Clinical Trial Expertise
First-in-human studies are the most scientifically significant stage of early clinical development. Every decision, from starting dose selection and escalation criteria to safety committee composition and stopping rules, carries scientific, regulatory and participant safety consequences that benefit from careful planning and integrated oversight from the outset.
Our teams bring experience in risk-based FIH study design, sentinel dosing strategies, adaptive dose-escalation frameworks and independent safety review committee support. Early regulator engagement positions programs for confident progression from the first dose cohort. Real-time integration of emerging safety data, PK/PD evidence and biomarker signals throughout escalation depends on close alignment between Clinical Trial Management and Regulatory Affairs.
Pharmacovigilance teams provide continuous safety monitoring, supporting adverse event reporting, SAE management, medical monitoring and the safety review processes that protect participants at every escalation decision point.
Pharmacokinetics and Pharmacodynamics Expertise
PK/PD evidence is the scientific foundation upon which dose selection, regimen optimization and Phase II design are built. Programs with clean, integrated PK/PD data enter proof-of-concept studies with greater confidence and produce stronger packages for health authority interactions and internal portfolio decisions.
Model-informed drug development, exposure-response modeling and biomarker integration transform pharmacokinetic data into actionable decisions. Population PK modeling characterises variability across patient subgroups. Exposure-response analysis establishes the relationship between drug levels and biological effect. Integrated biomarker data provides mechanistic support for dosing strategy and endpoint selection.
Specialist Pharmacokinetics, Clinical Data Management, Biostatistics and Regulatory Affairs operate within a single program team, delivering Noncompartmental Analysis (NCA), population PK modeling, exposure-response analysis and regulatory-ready PK/PD reporting.
Supporting Early Clinical Development Decisions
Phase I is where scientific interpretation of early data shapes every subsequent program decision. Go/no-go calls, dose selection for proof-of-concept studies, patient population refinement and Phase II endpoint design all depend on rigorous scientific analysis, integrated decision-making and regulatory readiness from the earliest stages.
Integrated Regulatory Affairs and Biotech CRO capabilities ensure regulatory positioning and program strategy remain aligned throughout early development, with scientific leadership informing both operational delivery and forward planning.
How Evestia Strengthens Early Clinical Development
Integrated support keeps Phase I programs advancing, with program continuity, scientific leadership and coordinated delivery maintained throughout every stage of early development.
First-in-Human Development
Transitioning from preclinical research into human studies is the most consequential step in clinical development. Risk-based FIH study design, robust dose-escalation frameworks and independent safety oversight support participant safety through integrated scientific and medical oversight, maintaining regulatory confidence and generating data that supports every subsequent development decision.
Dose Escalation Strategy
Establishing a safe and scientifically robust dosing approach requires integrated statistical expertise, adaptive design capability and experienced medical oversight. Well-designed escalation frameworks generate clearer evidence, support smoother progression and strengthen regulatory interactions throughout development.
PK/PD Evidence Generation
Informed development decisions depend on integrated pharmacokinetic and pharmacodynamic evidence generated and interpreted in real time. Model-informed drug development, exposure-response modeling and biomarker integration transform early safety and PK data into actionable program decisions that strengthen Phase II planning and scientific decision-making.
Regulatory Readiness
IND and CTA submissions, early regulatory authority interactions and pre-Phase II scientific advice meetings require programs to be strategically positioned from the earliest stages. Early regulatory engagement, parallel submission planning and proactive health authority interactions support efficient program progression through coordinated regulatory planning.
Extended Operational Bandwidth
Integrated specialist resource, available immediately through Full-Service CRO and FSP delivery, provides the operational depth programs need, helping biotechnology companies advance innovative Phase I programs alongside their scientific priorities and program priorities.
Building Momentum for Phase II
The evidence generated in Phase I shapes every subsequent development decision. Well-designed Phase I programs that generate clean PK/PD data, clear safety profiles and robust early efficacy signals create the strongest possible foundation for successful Phase II proof-of-concept studies, positive regulatory interactions and confident program communication and regulatory readiness.
Our Phase I CRO Services
Evestia Clinical integrates Clinical Operations, Pharmacokinetics, Biostatistics, Regulatory Affairs and all supporting functions within one coordinated Phase I delivery model, keeping safety data interpretation, PK/PD analysis and regulatory alignment consistent throughout early development.
Phase I Clinical Development Strategy
Successful early-phase programs begin with strong planning. Our teams support development strategy, study design optimization, endpoint selection, dose escalation planning, biomarker strategy and regulatory planning. Working alongside sponsors from the earliest stages strengthens program quality and scientific delivery.
First-in-Human (FIH) Studies
First-in-human studies require careful planning and execution. Our teams support FIH study design, safety monitoring, dose escalation programs, regulatory submissions and operational delivery, generating robust data while maintaining participant safety and regulatory compliance.
Learn moreClinical Trial Management
Our Clinical Trial Management teams provide project leadership, timeline management, vendor oversight, budget management, risk mitigation and stakeholder communication, ensuring studies remain on track from start-up through database lock.
Learn moreStudy Start-Up Services
Efficient study activation is critical in Phase I development. Our teams support feasibility assessments, site selection, regulatory submissions, ethics approvals, contract management and site activation.
Learn moreClinical Monitoring
Patient safety and protocol compliance are supported through Clinical Monitoring. Our teams provide site oversight, source data verification, regulatory compliance support, patient safety monitoring and quality management.
Learn moreClinical Trial Site Management
Selecting experienced research sites is critical to successful Phase I delivery. Our Site Management teams support site identification, qualification, training, engagement, recruitment oversight and performance management.
Learn morePharmacokinetics Services
Phase I programs rely heavily on Pharmacokinetics analysis. Our specialists provide Noncompartmental Analysis (NCA), population PK modeling, exposure-response analysis, dose optimization support and regulatory-ready reporting.
Learn moreClinical Data Management
High-quality Clinical Data Management supports real-time decision making. Our teams support database design, data cleaning, query management, real-time data review and submission-ready datasets.
Learn moreBiostatistics
Biostatistics plays a critical role in dose escalation and analysis. Our teams provide Statistical Analysis Plans, sample size support, interim analyzes, PK/PD statistical analysis and regulatory reporting.
Learn moreRegulatory Affairs
Early regulatory strategy is essential during Phase I development. Our Regulatory Affairs specialists support IND preparation, CTA submissions, health authority interactions, regulatory strategy and inspection readiness.
Learn moreMedical Writing
Clinical protocols and regulatory documents are developed by our Medical Writing teams, including protocols, investigator brochures, Clinical Study Reports and regulatory submissions.
Learn morePharmacovigilance
Safety oversight is supported through our Pharmacovigilance services. Our teams provide safety reporting, SAE management, medical monitoring support, signal detection and regulatory safety compliance.
Learn moreSponsors can also access dedicated resources through our Functional Service Provider (FSP) Solutions.
Phase I Expertise Across Key Therapeutic Areas
Disease-specific expertise informs Phase I study design, dose escalation strategies and biomarker development across every therapeutic area, strengthening scientific decision-making throughout early clinical development.
Phase I Oncology Studies
Supporting dose escalation, basket studies, combination therapies and biomarker-driven development across solid tumors, hematological malignancies and immuno-oncology.
Oncology CRORare Disease Phase I Programs
Helping sponsors maximize learning from limited patient populations, including orphan drug designation strategy and rare disease regulatory pathways.
Rare Disease CRONeurology Clinical Development
Supporting innovative neurological and neurodegenerative therapies across Alzheimer's disease, Parkinson's disease, ALS and other CNS conditions.
Neurology CROImmunology and Autoimmune Disease Studies
Supporting biologics, immune-mediated disease therapies and precision medicine programs across autoimmune and inflammatory conditions.
Immunology CROInflammatory Disease Development
Supporting inflammatory disease trials across rheumatology, dermatology and gastroenterology indications.
Inflammation Clinical TrialsAdvanced Therapy Development
Providing specialist support for ATMPs, gene therapies and cell-based therapies, including rare disease cell and gene programs requiring orphan drug regulatory strategies.
Cell & Gene Therapy CROWhy Sponsors Choose Evestia Clinical for Phase I Studies
Sponsors choose Evestia Clinical because we deliver the scientific depth, operational agility and senior access that early-phase development demands, with direct engagement from experienced Phase I specialists throughout program delivery.
Helping Sponsors Navigate First-in-Human Complexity
Phase I expertise in FIH study design, sentinel dosing strategies, safety review committee support and dose-escalation programs. Sponsors gain early-phase leadership capable of generating high-quality evidence while supporting regulatory readiness and participant safety.
Integrated PK/PD Expertise That Supports Better Decisions
Integrated Pharmacokinetics, Biostatistics and Clinical Data Management expertise supporting model-informed development, exposure-response modeling and biomarker-integrated dose optimization throughout early-phase development.
Flexible Partnerships That Scale Into Later Phases
Phase I support designed for biotechnology companies, providing strategic guidance, operational leadership and flexible delivery models that adapt to program evolution from first-in-human studies through Phase II and beyond.
Global Early-Phase Capability With Senior Access
Global CRO capabilities helping sponsors coordinate multinational early-phase programs, access specialist investigator networks and maintain consistent operational oversight across regulatory jurisdictions, with senior access maintained throughout.
Full-Service Delivery With Senior Access
Phase I programs delivered through our integrated Full-Service CRO model, combining Clinical Operations, Regulatory Affairs, Data Management, Biostatistics, Pharmacovigilance and Medical Writing through multidisciplinary collaboration and coordinated delivery. Faster decisions, direct senior access throughout.
Phase I Delivery Through Full-Service and FSP Models
Phase I expertise is available through our integrated Full-Service CRO model or as dedicated embedded resource through FSP Solutions, providing the flexibility to align with internal team structures and governance requirements at every stage.
Phase I CRO Support for Biotech Companies
Biotechnology companies advancing innovative science benefit from integrated scientific partnership, scalable early-phase support and collaborative program leadership that adapts alongside each program. Evestia Clinical embeds within sponsor governance structures, providing scientific collaboration and operational capability from first-in-human initiation through phase transition.
Early-phase resource adapts as program requirements evolve, supporting scientific development and program continuity from first dose through final analysis. As a dedicated Biotech CRO, programs are accessible through our Full-Service CRO model or via FSP Solutions.
Clinical Development Support Across Every Phase
Successful clinical development depends on maintaining scientific and operational continuity from Phase I through later-stage studies. Sponsors who work with Evestia Clinical from early development gain a long-term partner whose program knowledge deepens as studies progress, preserving program continuity and retaining program knowledge throughout development.
Phase I CRO
First-in-human and early-phase clinical development.
Phase II CRO
Strong Phase I evidence creates the strongest possible foundation for Phase II proof-of-concept studies, where dose optimization and efficacy signals are established to support regulatory and commercial progression.
Learn morePhase III CRO
Therapies that demonstrate safety and efficacy progress into Phase IV & Post-Marketing pivotal registration studies. Continuity of clinical development expertise from Phase I through registration protects program knowledge and accelerates the path to regulatory submission.
Learn moreFrequently Asked Questions About Phase I Clinical Trials
Explore Related Clinical Development Services
Service Pages
Development Phases
Therapeutic Expertise
Building Strong Foundations for Clinical Success
Phase I CRO expertise, first-in-human leadership, integrated Full-Service and FSP delivery, and collaborative scientific partnership give sponsors the integrated partner they need to generate robust early evidence and support successful program progression into Phase II and beyond.
Whether planning a first-in-human study, dose-escalation program or early-phase patient trial, Evestia Clinical provides the scientific depth, operational agility and integrated expertise that Phase I programs require.